Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.
- Published In:
- The lancet. Diabetes & endocrinology, 13(7), 556-567 (2025)
- Authors:
- Billings, Liana K, Andreozzi, Francesco, Frederiksen, Marie, Gourdy, Pierre, Gowda, Amoolya, Ji, Linong, Pletsch-Borba, Laura, Suzuki, Ryo, Unnikrishnan, A G, Vianna, André G D
- Database ID:
- RPEP-10159
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10159APA
Billings, Liana K; Andreozzi, Francesco; Frederiksen, Marie; Gourdy, Pierre; Gowda, Amoolya; Ji, Linong; Pletsch-Borba, Laura; Suzuki, Ryo; Unnikrishnan, A G; Vianna, André G D. (2025). Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.. The lancet. Diabetes & endocrinology, 13(7), 556-567. https://doi.org/10.1016/S2213-8587(25)00052-X
MLA
Billings, Liana K, et al. "Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.." The lancet. Diabetes & endocrinology, 2025. https://doi.org/10.1016/S2213-8587(25)00052-X
RethinkPeptides
RethinkPeptides Research Database. "Once-weekly IcoSema versus multiple daily insulin injections..." RPEP-10159. Retrieved from https://rethinkpeptides.com/research/billings-2025-onceweekly-icosema-versus-multiple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.